# Science Strikes Back at Cancer

> New cancer drugs show survival gains in trials, with AI and oil prices spiking.
- Title: Science Strikes Back at Cancer · The Motley Fool | Shortify
- Summary: New cancer drugs show survival gains in trials, with AI and oil prices spiking. Cancer trials show survival improvements, AI spending jitters and oil prices…
- Keywords: cancer, oncology, esmo, astrazeneca, ellilly, moderna, amgen, roche, summit, s&p 500, oil prices, Science
- Source: The Motley Fool — https://fool.com/investing/breakfast-news/2026/10/26/breakfast-news-science-strikes-back-at-cancer
- Author: TMF Breakfast News
- Published: 2026-10-26T11:30:02+00:00
- Read time: 1 min
- Topics: cancer, oncology, esmo, astrazeneca, ellilly, moderna, amgen, roche, summit, s&p 500, ai, oil prices
## Oncology Pulse: Latest Breakthroughs
The European Society for Medical Oncology Congress in Madrid shows strong survival gains from new cancer drugs.

> AstraZeneca's stomach cancer drug Sone-Ve doubled median survival to 10 months from 5 months in patients who had already tried at least two treatments.
## AstraZeneca Drug Shows Survival Gain
AstraZeneca's stomach cancer drug Sone-Ve doubled median survival to 10 months from 5 months in patients who had already tried at least two treatments.
## Eli Lilly's Lung Cancer Drug
Eli Lilly's Olomorasib shrank tumors in 62% of 77 patients with KRAS G12C-mutated lung cancer.
## Moderna and Merck's Cancer Vaccine
Moderna and Merck's personalized cancer vaccine cut recurrence risk by 42% when added to Keytruda.
## Amgen's Lung Cancer Therapy
Amgen's Imdelltra extended median survival to 21.1 months versus 12.7 months for Imfinzi alone in small cell lung cancer.
## Roche's KRAS Inhibitor
Roche's divarasib beat rival drugs from Amgen and Bristol-Myers Squibb in a head-to-head trial, nearly doubling response rates.
## Summit's Biliary Cancer Trial
Summit's Ivonescimab combined with chemotherapy top Imfinzi plus chemotherapy in first-line biliary tract cancer in China.
## AI Jitters and Oil Spikes
U.S. stocks dropped as AI spending jitters and surging oil prices triggered a sell-off, with Brent crude hitting $116.72.
## Fed's Next Move
The Federal Reserve ends its two-day meeting Wednesday with 90% odds of holding rates steady, but inflation uncertainty may lead to a December rate hike.
## Earnings Week Highlights
Visa, Alphabet, Sterling Infrastructure, EMCOR, Mastercard, Intel, Reddit, and Amazon report earnings this week with key metrics for investors.
## TransDigm's Market Performance
TransDigm's stock is down 10% since March but shows strong sales growth and resilient cash flow despite market concerns.
## Key takeaway

Cancer trials show survival improvements, AI spending jitters and oil prices drive market volatility.